Clinical Trial

Novel mRNA-LNP-Based Intratumoral Immunotherapy in Patients With Advanced Malignant Solid Tumors

Study acronym: mRNA-LNP
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
PMC2129G12 is an investigational intratumorally administered messenger RNA-lipid nanoparticle (mRNA-LNP) immunotherapy designed to enable localized, transient expression of a humanized EpCAM-targeted CD3-engaging bispecific antibody together with the immunostimulatory cytokines to kill tumors by recruited immune T cells.
Trial Details
NCT Number NCT07587879
Lead Sponsor IntraAb, Inc.
Conditions Advanced Solid Tumor
Enrollment 60 participants
Start Date 2027-01-01
Primary Completion 2030-01-01 (estimated)
Study Completion 2031-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-14